Zusammenfassung
Die pulmonale Strombahn unterscheidet sich in wesentlichen Punkten von der Strombahn anderer Organe: Das Gefäßsystem der Lunge ist ein Niederdrucksystem. Die arteriellen Drücke und vaskulären Widerstände betragen nur ca. ein Achtel der Werte des großen Kreislaufes.
Chapter PDF
Similar content being viewed by others
Literatur
Abenhaim L, Moride Y, Brenot F et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335: 609–616.
Adnot S, Andrivet P, Chabrier PE et al. (1989) Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. J Clin Invest 83: 986–993.
Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B (1992) Short and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 102: 1407–1412.
Archer SL, Souil E, Dihn-Xuan AT, Schremmer B, Mercier JC, El Yaagoubi E (1998) Molecular identification of the role of voltage-tagged K+ channels, Kv 1.5 and 2.1 in hypoxic pulmonary vasoconstriction and control of resting membrane potentials in rat arterial myocytes. J Clin Invest 10: 1–12.
Archer SL, Kjaballah K, Humbert M, Weir EK, Fartoukh M, Simmonneau G, Dinh-Yuan AT (1998) Nitric oxide deficiency in pulmonary hypertension associated with use of the anorectic agents fenfluramine and dexfenfluramine. Am J Respir Crit Med 157: 594.
Asherson RA, Khamashta MA, Ordi-Ros J (1989) The primary antiphospholipid syndrome: major clinical and serological features. Medicine 68: 366–374.
Bärtsch P, Waber U, Haeberli A, Maggiorni M, Kriemler S, Oelz O, Sträub WP (1987) Enhanced fibrin formation in high altitude pulmonary edema. J Appl Physiol 63: 752–757.
Bärtsch P, Vock P, Maggiorni M et al. (1990) Respiratory symptoms, radiographic and physiologic correlations at high altitude. In: Coates G, Remmers J, Sutton J (eds) Hypoxia: the Adaptations. Decker, Toronto, pp 241–245.
Bärtsch P (1997) High altitude pulmonary edema. Respiration 64: 435–443.
Barman SA (1995) Effect of catecholamines on pulmonary circulation at elevated vascular tone. J Appl Physiol 78: 1452–1458.
Barst, RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Int Med 121: 409–415.
Barst RJ, Rubin LJ, Long A and the Pulmonary Hypertension Study Group (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334: 296–302.
Bartosik I, Eskilsson J, Scheja A, Abesson A (1996) Intermittent iloprost therapy of pulmonary hypertension in scleroderma — a pilot study (Letter). Br J Rheumatol 35: 1187–1188.
Bartram SA, Denton CP, du Bois RM, Black CM (1995) Sustained improvement in scleroderma associated pulmonary hypertension following pulsed intravenous prostacyclin therapy. Arthritis Rheum 38: 307.
Cargill RI, Lipworth BJ (1995) Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans. Thorax 50: 183–185.
Carosi JA, Mclntire LV (1993) Effects of cyclicyl strain on the production of vasoactive materials by cultured human and bocine endothelial cells. Eur Respir Rev 3: 598–608.
Chapelier A, Vouhe P, Macchiarini P et al. (1993) Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. J Thrac Cardiovasc Surg 106: 299–307.
Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70–75.
Cool SD, Tuder RM, Voelekl NF (1997) Plexiform pulmonary vascular lesions in scleroderma and AIDS: is there a common pathogenesis? Hum Pathol 28: 434–442.
Cremona, G, Higgenbottam T (1995) Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol 75: 67A–71A.
Davis P, Burke G, Reid L (1986) The structure of the wall of the rat intraacinar pulmonary artery: an electron microscopic study of microdissected preparations. Microvasc Res 32: 50–63.
Dickey BF, Myers AR (1988) Pulmonary manifestations of collagen-vascular diseases, vol 2, part 6,. In: Fishman AP (ed) Pulmonary diseases and disorders. McGraw-Hill, New York, pp 645–663.
Dinh-Xuan AT, Higenbottam TW, Clelland C, Pepke-Zaba J, Cremona G, Wallwork J (1990) Impairment of pulmonary endothelium-dependent relaxations in patients with Eisenmenger’s syndrome. Br J Pharmacol 99: 9–10.
Erkan F, Cadvar T (1992) Pulmonary vasculitis in Behcet’s disease. Am Rev Respir Dis 146: 232–239.
Gaßner A, Friedrich L, Vagner M, Pichler M (1985) Pulmonale Hypertonie bei chronischer Atemwegsobstruktion. Dtsch Med Wochenschr 110: 247–252.
Gaßner A, Friedrich L, Sommer G (1986) Ventrikuläre Rhythmusstörungen bei pulmonaler Hypertonie und chronischer obstruktiver Lungenerkrankung. Dtsch Med Wochenschr 111: 1218–1220.
Giaid A, Yanagisawa M, Langleben D et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732–1739.
Giaid A, Saleh D (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214–221.
Grimminger F, Weissmann N, Spriesterbach R, Becker E, Rosseau S, Seeger W (1995) Effects of NADPH Oxidase-inhibitors on hypoxic vasoconstriction in buffer-perfused rabbit lungs. Lung Cell Mol Biol 268: 747–752.
Hackett PH, Rennie D, Levine HD (1976) The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 11: 1149–1154.
Haufe, MC, Gerzer R, Weil J, Ernst JE, Theisen K (1988) Verapamil impairs secretion of stimulated atrial natriuretic factor in humans. J Am Coll Cardiol 11: 1199–1203.
Herget J, Palecek F, Preclik P, Cermakova M, Vizek M, Petrovicka M (1981) Pulmonary hypertension induced by repeated pulmonary inflammation in the rat. J Appl Physiol 51: 755–761.
Herve J, Launay JM, Scrobohaci ML et al. (1995) Increase plasma serotonin in primary pulmonary hypertension. Am J Med 99: 249–254.
Herve P, Lebrec D, Brenot F, Simmoneau G, Humbert M, Sitbon O, Duroux P (1998) Pulmonary vascular disorders in portal hypertension. Eur Respir J 11: 1153–1166.
Higgenbottam T, Wheeldon D, Wells F, Wallwork J (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1: 1046–1047.
Higgenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Ccaine N, Wallwork J (1993) The value of prostacyclin (epoprostenol) and heart-lung transplantation for severe pulmonary hypertension. Br Heart J 70: 366–370.
Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Eng J Med 342: 1866–1870.
Hochstrasser J, Nanzer A, Oelz O (1986) Das Höhenlungenödem in den Schweizer Alpen. Beobachtungen über Inzidenz, Klinik und Verlauf bei 50 Patienten der Jahre 1980–1984. Schweiz Med Wochenschr 116: 866–873.
Humbert M, Monti G, Fartoukh M et al. (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11: 554–559.
Hyman AL, Kadowitz PJ (1979) Pulmonary vasodilator activity of prostacyclin in the cat. Circ Res 45: 404–409.
Ichonese F, Adrie C, Hurford WE, Zapol WM (1995) Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. J Appl Physiol 78: 1288–1295.
Janssens SP, Bloch KD, Nong Z, Gerard RD, Zoldhelyi P, Collen D (1996) Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest 98: 317–324.
Kalra L, Bone MF (1993) Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. Am J Med 94: 419–423.
Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ (1995) Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 91: 2028–2035.
Klinger JR, Petit RA, Warburton RR, Wrenn DS, Arnal F, Hill NS (1993) Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats. J Appl Physiol 75: 1615–1623.
Kobayashi T, Koyama S, Kubo K, Fukushima M, Kusama S (1987) Clinical features of patients with high-altitude pulmonary edema in Japan. Chest 92: 814–821.
Kshettry VR, Kroshus TJ, Savik K, Hertz MI, Bolman M (1996) Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Chest 110: 704–709.
Lee S, Wang WW, Lanzillo JJ, Fanburg BL (1994) Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 266: 46–52.
Lee S, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM (1998) Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101: 927–934.
Loscalzo J (1995) Nitric oxide and vascular disease. N Engl J Med 333: 251–253.
Martin-Duran R, Larman M, Trugeda A et al. (1986) Comparison of Doppler-determined elevated pulmonary arterial pressure with pressure measured at cardiac catheterization. Am J Cardiol 57: 859–863.
Mata J de la, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ (1994) Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 37: 1528–1533.
Mathur PN, Powles ACP, Pugsley SO, McEwan MP, Campbell EJM (1981) Effect of digoxin on right ventricular function in severe chronic airflow obstruction. Ann Intern Med 95: 283–288.
McDonnell PJ, Toye PA, Hutchins GM (1983) Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 127: 437–441.
McQuillan LP, Leung GK, Marsden PA, Kostyk SK, Kourembanas S (1994) Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 267: 1921–1927.
Moncada S, Vane JR (1979) Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 300: 1142–1147.
Moncada S, Palmer R, Higgs E (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109–142.
Moser KM, Auger WR, Fedullo PF (1990) Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 81: 1735–1743.
Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, W Seeger (1996) Aerosolised prostacyclin and iloprost in primary pulmonary hypertension. Ann Intern Med 124: 820–824.
Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Höper M, Behr J, Kleber F-X, Seeger W, and the German PPH study group (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH study group. Ann Intern Med 132 (6): 435–443.
Ono S, Westcott JY, Voelkel NF (1992) PAF antagonists inhibit pulmonary vascular remodelling induced by hepobaric hypoxia in rats. J Appl Physiol 73: 1084–1092.
Porter TR, Taylor DO, Cycan A, Fields J, Bagley CW, Pandian NG, Mohanty PK (1993) Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol 22: 1418–1424.
Reeve HL, Archer SL, Weir EK (1997) Ion channels in the pulmonary vasculature. Pulm Pharm Therap 10: 243–252.
Rich S, Pietra GG, Kieras K, Hart K, Brundage BH (1986) Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 105: 499–502.
Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76–81.
Rubin LJ, Mendoza J, Hood M et al. (1990) Treatment of pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med 112: 485–491.
Rubin LJ (1997) Current Concept — Primary pulmonary hypertension. N Engl J Med 336: 111–116.
Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG (1988) Long-term treatment of chronic obstructive lung disease by nifedipine: an 18-month haemodynamic study. Europ Resp J 1: 716–720.
Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, Guerrero L (1994) Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89: 1733–1744.
Singh I, Kapila CC, Khanna PK, Nanda RB, Rao BDP (1965) High-altitude pulmonary oedema. Lancet i: 229–234.
Speich R, Jenni R, Opravil M, Pfab M, Russi EW (1991) Primary pulmonary hypertension in HIV infection. Chest 100: 1268–1271.
Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275–285.
Tuxen DV, Powles AC, Mathur PN, Pugsley SO, Campbell EJ (1984) Detrimental effects of hydralazine in patients with chronic airflow obstruction and pulmonary hypertension. A combined hemodynamic and radionuclide study. Am Rev Respir Dis 129: 388–395.
Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM (1998) Primary pulmonary hypertension between inflammation and cancer. Chest 114: 225–230.
Wagenvoort CA (1960) Vasoconstriction and medical hypertrophy in pulmonary hypertension. Circulation 22: 535–546.
Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W (1993) Aerosolized prostacyclin reduces pulmonary artery pressure and improves gas exchange in the adult respiratory distress syndrome (ARDS). Lancet 342: 961–962.
Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W (1995) Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 151: 724–730.
Wei CM, Lerman A, Rodeheffer RJ, McGregor CG et al. (1994) Endothelin in human congestive heart failure. Circulation 89: 1580–1586.
Winter RJ, Zhao L, Krausz T, Hughes JM (1991) Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Am Rev Respir Dis 144: 1342–1346.
Wood P (1958) Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 20: 557–570.
Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF (1998) 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 157: 219–229.
Youngson C, Nurse C, Yeger H, Cutz E (1993) Oxygen sensing in airway chemoreceptors. Nature 365: 153–155.
Yuan JX, Aldinger AM, Juhaszowa M et al. (1998) Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 14: 1400–1406.
Zapol W, Rimar S, Gillis N, Marietta M, Boslaw C (1994) Nitric oxide and the lung. Am J Respir Crit Care Med 149: 1375–1380.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Grimminger, F., Walmrath, D., Seeger, W. (2002). Pulmonale Hypertonie. In: Matthys, H., Seeger, W. (eds) Klinische Pneumologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-08120-4_29
Download citation
DOI: https://doi.org/10.1007/978-3-662-08120-4_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-08121-1
Online ISBN: 978-3-662-08120-4
eBook Packages: Springer Book Archive